Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

The future may be getting brighter in terms of reducing the threat of the human immunodeficiency virus (HIV), infectious disease experts told Newsweek. With new treatments and maybe even a vaccine ...

(MENAFN- Caribbean News Global) GENEVA, Switzerland – WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

On Friday, Morgan Stanley (NYSE:MS) upgraded Gilead Sciences (NASDAQ:GILD)' stock rating from Equal-weight to Overweight and increased the price target to $113 from the previous $87. The upgrade comes ...